Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Keita Ishido"'
Autor:
Shota Kuwabara, Yuta Takeuchi, Osamu Sato, Tomoko Mizota, Masaomi Ichinokawa, Katsuhiko Murakawa, Yuma Aoki, Keita Ishido, Koichi Ono, Satoshi Hirano
Publikováno v:
BMC Surgery, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Pancreatic ductal carcinoma (PDAC) is an extremely poor prognostic disease. Even though multidisciplinary treatment for PDAC has developed, supportive therapies, such as nutritional therapy or perioperative rehabilitation to susta
Externí odkaz:
https://doaj.org/article/a15cf359a3084e56ada668f8f6a63888
Autor:
Shin Emoto, Shigenori Homma, Tadashi Yoshida, Nobuki Ichikawa, Yoichi Miyaoka, Hiroki Matsui, Ryo Takahashi, Keita Ishido, Takuya Otsuka, Tomoko Mitsuhashi, Takehiko Katsurada, Akinobu Taketomi
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background The improved prognosis of Crohn’s disease may increase the opportunities of surgical treatment for patients with Crohn’s disease and the risk of development of colorectal cancer. We herein describe a patient with Crohn’s dis
Externí odkaz:
https://doaj.org/article/4d0574d72f0740f2ace909a9ac5afcbe
Autor:
Shoki Sato, Naoto Senmaru, Keita Ishido, Takahiro Saito, Saseem Poudel, Jun Muto, Yasuhito Syouji, Ryunosuke Hase, Satoshi Hirano
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Background Pembrolizumab is an immune checkpoint inhibitor and is an anti-human programmed cell death-1 (PD-1) monoclonal antibody. Pembrolizumab is used for non-small cell lung carcinoma with high programmed cell death ligand-1 (PD-L1) expr
Externí odkaz:
https://doaj.org/article/372cc1695965475fb3b31e73835d2c3d
Autor:
Shota Kuwabara, Yuka Takakuwa, Keita Ishido, Yuma Aoki, Kazuyuki Yamamoto, Yasuhito Shoji, Akira Fukunaga, Tatsunosuke Ichimura, Hiroto Manase, Satoshi Hirano
Publikováno v:
American Journal of Case Reports; 8/15/2024, Vol. 25, p1-6, 6p